Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer

PURPOSE: To define the maximum tolerated dose (MTD), toxicities, and pharmacokinetics of 17-allylamino-17-demethoxygeldanamycin (17-AAG) when administered using continuous and intermittent dosing schedules. EXPERIMENTAL DESIGN: Patients with progressive solid tumor malignancies were treated with 17-...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Solit, David B., Ivy, S. Percy, Kopil, Catherine, Sikorski, Rachel, Morris, Michael J., Slovin, Susan F., Kelly, W. Kevin, DeLaCruz, Anthony, Curley, Tracy, Heller, Glenn, Larson, Steven, Schwartz, Lawrence, Egorin, Merrill J., Rosen, Neal, Scher, Howard I.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2007
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3203693/
https://ncbi.nlm.nih.gov/pubmed/17363532
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-06-1863
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller